ClinicalTrials.gg
Not yet recruitingNCT07384936Updated Feb 3, 2026

Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

An interventional study of Topefilgrastim Injection and Topefilgrastim Injection in Preeclampsia, sponsored by Fang Wang. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Fang Wang · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.

Planned enrollment
13th of 19
100 · median 180
Started
2026
the only one that year
No phase
12 of 36
5 open now
Primary completion
2027-05
later than 7 of 12 live
Registered
36th of 36
by date
Lead sponsor
1 of 36
Fang Wang

Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 36th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pre-Eclampsia with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, prospective investigation designed to enroll 100 high-risk pregnant subjects with preeclampsia (PE). Participants will be allocated in a 2:2:1 ratio to one of three groups: the Topefilgrastim 0.5mg/biweekly group, the Topefilgrastim 1mg/biweekly group, or the control group, based on investigator judgment and patient preference. The overall study consists of three parts: a screening period, a treatment period, and a follow-up period.

03

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • Preeclampsia
  • Topefilgrastim Injection
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the study, be able to understand, and sign the form.
  • Aged 18 to 45 years (inclusive) at the time of signing the informed consent form.
  • Assessed as high-risk for preeclampsia at gestational weeks 11-13, defined as either:

A risk value of ≥1/100 based on the simplified Fetal Medicine Foundation (FMF) model, OR A high-risk result from serum biomarker screening (sFlt-1, PLGF, sFlt-1/PLGF ratio). (See Appendix for details)

  • Gestational weeks 11-13 at enrollment.
  • Singleton intrauterine pregnancy (confirmed by transvaginal or transabdominal ultrasound).

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric disorder not adequately controlled by medication.
  • Unexplained vaginal bleeding at screening.
  • Known uterine malformation.
  • Evidence of positive serology for , (HBsAg positive), (anti-HCV antibody positive), or syphilis.
  • Known proliferative retinopathy.
  • Presence of severe organic disease or any other condition that, in the judgment of the investigator, makes the subject unsuitable for study participation.
  • Planned or current use of medications with potential drug-drug interactions with human granulocyte colony-stimulating factor (G-CSF) analogs, such as lithium.
  • Known allergy to rhG-CSF products or their components, or allergy to recombinant human proteins/peptides derived from E. coli.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Topefilgrastim 0.5mg Group

    Drug: Topefilgrastim Injection

  • Experimental
    Topefilgrastim 1mg Group

    Drug: Topefilgrastim Injection

  • No intervention
    Control Group

Interventions

  • DrugTopefilgrastim Injection

    Subjects will receive subcutaneous injection of 0.5 mg Topefilgrastim starting from Week 1 Day 1 (W1D1), with a frequency of once every two weeks, for at least 8 consecutive weeks.

  • DrugTopefilgrastim Injection

    Subjects will receive subcutaneous injection of 1 mg Topefilgrastim starting from Week 1 Day 1 (W1D1), with a frequency of once every two weeks, for at least 8 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. soluble fms-like tyrosine kinase-1(sFlt-1)

    Time frame: Gestational weeks 11-13;15-17;24-28

  2. placental growth factor(PLGF)

    Time frame: Gestational weeks 11-13;15-17;24-28

  3. sFlt-1/PLGF ratio

    Time frame: Gestational weeks 11-13;15-17;24-28

Secondary outcomes

  1. Incidence of preeclampsia

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  2. Incidence of early-onset preeclampsia

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  3. Incidence of PE-associated Preterm Delivery

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  4. Miscarriage rate

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  5. Preterm birth rate

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  6. Gestational age at delivery

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  7. Neonatal birth weight

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  8. Incidence of small for gestational age (SGA) neonates

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  9. Admission rate to the neonatal ward

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  10. NICU admission rate

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  11. Adverse Events (AEs)

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  12. Serious Adverse Events (SAEs)

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  13. Frequency of Adverse Events

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  14. Frequency of Serious Adverse Events

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  15. Severity of Adverse Events

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  16. Severity of Serious Adverse Events

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  17. Fetal Death

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  18. Perinatal Death

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  19. Incidence of congenital malformations

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  20. Body Temperature

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  21. Pulse

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  22. Respiratory Rate

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  23. Blood Pressure

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  24. Height

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  25. Weight

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  26. Number of Participants with Abnormal Laboratory Parameters Findings

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  27. Number of subjects with clinically significant abnormal findings in radiological examinations

    including maternal/fetal or perinatal infants

    Time frame: From 11 weeks of pregnancy to 6 weeks postpartum

  28. Resistance Index (RI) of Uterine Spiral Arteries

    Time frame: Gestational weeks 11-13;15-17;24-28

  29. Pulsatility Index (PI) of Uterine Arteries

    Time frame: Gestational weeks 11-13;15-17;24-28

  30. Systolic to Diastolic Ratio (S/D ratio) of Uterine Spiral Arteries

    Time frame: Gestational weeks 11-13;15-17;24-28

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2027, 16 months later.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 3, 2026
StartEst.
Jan 31, 2026
Primary completionEst.
May 2027
CompletionEst.
Dec 2027
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07384936
Lead sponsor
Fang Wang
Responsible party
Fang Wang (Chief physician, Lanzhou University Second Hospital) — Sponsor-investigator
First posted
Feb 3, 2026
Start date
Jan 31, 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

Fang Wang
Contact
ery_fwang@lzu.edu.cn
13919302888
Fang Wang
principal investigator · Lanzhou University Second Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion